Patents by Inventor Hartmut Greiner

Hartmut Greiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic heteroaromatic compounds
    Patent number: 9249140
    Abstract: Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: February 2, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Felix Rohdich, Christina Esdar, Mireille Krier, Hartmut Greiner
  • BICYCLIC HETEROAROMATIC COMPOUNDS
    Publication number: 20150218155
    Abstract: Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 6, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Felix Rohdich, Christina Esdar, Mireille Krier, Hartmut Greiner
  • Pyrimidine derivatives as FAK inhibitors
    Patent number: 8906916
    Abstract: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 9, 2014
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Christina Esdar, Hartmut Greiner
  • Azaheterocyclic compounds as kinase inhibitors
    Patent number: 8859581
    Abstract: The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumors and/or diseases in the development or course of which kinases are involved.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: October 14, 2014
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Andree Blaukat, Wolfgang Staehle, Hartmut Greiner, Maria Kordowicz
  • PYRIMIDINE DERIVATIVES AS FAK INHIBITORS
    Publication number: 20130158005
    Abstract: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: July 19, 2011
    Publication date: June 20, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Timo Heinrich, Christina Esdar, Hartmut Greiner
  • Imidazothiadiazole derivatives
    Patent number: 8389554
    Abstract: Novel imidazo[2,1-b][1,3,4]thiadiazole derivatives of formula (I) wherein R1 and R2 have the meaning according to claim 1, are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: March 5, 2013
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Emilie Rossignol, Dominique Swinnen
  • 5-cyanothienopyridines for the treatment of tumours
    Patent number: 8202882
    Abstract: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: June 19, 2012
    Assignee: Merck Patent Gesellschaft MIT Beschränkter Haftung
    Inventors: Guenter Hoelzemann, Ulrich Graedler, Hartmut Greiner, Christiane Amendt, Djordje Musil, Per Hillertz
  • ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS
    Publication number: 20120101095
    Abstract: Novel alkoxy-thienopyrimidine derivatives of formula (I) wherein R1 and R2 have the meaning according to claim 1, are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: May 27, 2010
    Publication date: April 26, 2012
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Hartmut Greiner, Christiane Amendt, Frank Zenke
  • Triazole derivatives
    Patent number: 8093240
    Abstract: Novel triazole derivatives are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: November 24, 2006
    Date of Patent: January 10, 2012
    Assignee: Merck Patent GmbH
    Inventors: Bertram Cezanne, Christiane Amendt, Hartmut Greiner, Ulrich Graedler, Guenter Hoelzemann
  • Triazabenzo[E]azulene derivatives for the treatment of tumors
    Patent number: 8063040
    Abstract: Novel triazabenzo[e]azulene derivatives of the formula, (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: September 29, 2007
    Date of Patent: November 22, 2011
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Christiane Amendt
  • Heterocyclic substituted bisarylurea derivatives
    Patent number: 8003657
    Abstract: The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: August 23, 2011
    Assignee: Merck Patent GmbH
    Inventors: Frank Stieber, Alfred Jonczyk, Guenter Hoelzemann, Hans-Peter Buchstaller, Lars Thore Burgdorf, Wilfried Rautenberg, Hartmut Greiner
  • IMIDAZOTHIADIAZOLE DERIVATIVES
    Publication number: 20110130396
    Abstract: Novel imidazo[2,1-b][1,3,4]thiadiazole derivatives of formula (I) wherein R1 and R2 have the meaning according to claim 1, are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: July 1, 2009
    Publication date: June 2, 2011
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Emilie Rossignol, Dominique Swinnen
  • Diazepinoes
    Patent number: 7943608
    Abstract: The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the development or course of which kinases are involved.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: May 17, 2011
    Assignee: Merck Patent GmbH
    Inventors: Melanie Schultz, Lars Thore Burgdorf, Dirk Finsinger, Andree Blaukat, Hartmut Greiner, Christina Esdar
  • THIENOPYRIMIDINES
    Publication number: 20110028472
    Abstract: Novel thienopyrimidines of the formula (I), in which R1, R2 and X have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: March 23, 2009
    Publication date: February 3, 2011
    Applicant: MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Christiane Amendt, Frank Zenke
  • 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS
    Publication number: 20100234369
    Abstract: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: September 19, 2008
    Publication date: September 16, 2010
    Inventors: Guenter Hoelzemann, Ulrich Graedler, Hartmut Greiner, Christiane Amendt, Djordje Musil, Per Hillertz
  • Oxindoles as kinase inhibitors
    Patent number: 7781475
    Abstract: The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: August 24, 2010
    Assignee: Merck Patent GmbH
    Inventors: Lars Thore Burgdorf, David Bruge, Hartmut Greiner, Maria Kordowicz, Christian Sirrenberg, Frank Zenke
  • OXINDOLES AS KINASE INHIBITORS
    Publication number: 20100197757
    Abstract: The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition.
    Type: Application
    Filed: April 15, 2010
    Publication date: August 5, 2010
    Inventors: Lars Thore BURGDORF, David Bruge, Hartmut Greiner, Maria Kordowicz, Christian Sirrenberg, Frank Zenke
  • NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20100160356
    Abstract: The invention relates to compounds of the formula I, to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the formation or course of which protein kinases are involved.
    Type: Application
    Filed: March 8, 2007
    Publication date: June 24, 2010
    Inventors: Timo Heinrich, Wolfgang Staehle, Hartmut Greiner, Andree Blaukat
  • Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors
    Publication number: 20100063028
    Abstract: Novel triazabenzo[e]azulene derivatives of the formula, (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: September 29, 2007
    Publication date: March 11, 2010
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Christiane Amendt
  • PHENOXY-PIPERIDINES FOR THE TREATMENT OF DISEASES SUCH AS SCHIZOPHRENIA AND DEPRESSION
    Publication number: 20090247584
    Abstract: Compounds of the formula (I), in which R1, R2?, R2?, R2??, R3 and n are as defined in Claim 1, are effectors of the nicotinic and/or muscarinic acetylcholine receptor and are suitable for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.
    Type: Application
    Filed: February 26, 2009
    Publication date: October 1, 2009
    Inventors: Gunter HOLZEMANN, Helmut Prucher, Kai Schiemann, Joachim Leibrock, Hartmut Greiner, Christa Burger, Laurie von Melchner